KR102493735B1 - 퓨로세마이드의 피하 투여용 약학 제형 - Google Patents

퓨로세마이드의 피하 투여용 약학 제형 Download PDF

Info

Publication number
KR102493735B1
KR102493735B1 KR1020217018012A KR20217018012A KR102493735B1 KR 102493735 B1 KR102493735 B1 KR 102493735B1 KR 1020217018012 A KR1020217018012 A KR 1020217018012A KR 20217018012 A KR20217018012 A KR 20217018012A KR 102493735 B1 KR102493735 B1 KR 102493735B1
Authority
KR
South Korea
Prior art keywords
furosemide
pharmaceutical formulation
tris
liquid pharmaceutical
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018012A
Other languages
English (en)
Korean (ko)
Other versions
KR20210075211A (ko
Inventor
스콧 에이 마이클스
피터 문텐담
글렌 알 라슨
Original Assignee
에스씨파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스씨파마슈티칼스 인코포레이티드 filed Critical 에스씨파마슈티칼스 인코포레이티드
Publication of KR20210075211A publication Critical patent/KR20210075211A/ko
Application granted granted Critical
Publication of KR102493735B1 publication Critical patent/KR102493735B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217018012A 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형 Active KR102493735B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
US61/808,962 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide
KR1020157031677A KR102266460B1 (ko) 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157031677A Division KR102266460B1 (ko) 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형

Publications (2)

Publication Number Publication Date
KR20210075211A KR20210075211A (ko) 2021-06-22
KR102493735B1 true KR102493735B1 (ko) 2023-01-30

Family

ID=51659206

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217018012A Active KR102493735B1 (ko) 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형
KR1020157031677A Active KR102266460B1 (ko) 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157031677A Active KR102266460B1 (ko) 2013-04-05 2014-04-03 퓨로세마이드의 피하 투여용 약학 제형

Country Status (14)

Country Link
US (5) US9884039B2 (https=)
EP (3) EP2981258B8 (https=)
JP (2) JP6415535B2 (https=)
KR (2) KR102493735B1 (https=)
CN (1) CN105431145B (https=)
AU (1) AU2014248164B2 (https=)
CA (1) CA2908935C (https=)
DK (1) DK2981258T3 (https=)
ES (1) ES2823589T3 (https=)
IL (1) IL241917B (https=)
MX (1) MX367165B (https=)
PT (1) PT2981258T (https=)
SG (2) SG11201508251RA (https=)
WO (1) WO2014165660A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2022031959A1 (en) 2020-08-05 2022-02-10 Scpharmaceuticals Inc. Methods of treatment using furosemide
JP2024512650A (ja) 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
WO1992021769A1 (en) * 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
EP0808171A2 (en) * 1995-02-10 1997-11-26 G.D. SEARLE & CO. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
MX2009000385A (es) * 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2334302B1 (en) * 2008-09-09 2018-03-21 Cima Labs Inc DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE
US20110060280A1 (en) * 2009-09-04 2011-03-10 Sean Caffey Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
PT2981258T (pt) 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) * 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) * 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. Devarakonda et al., INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007) Vol.345, pp.142-153*

Also Published As

Publication number Publication date
CN105431145B (zh) 2019-12-10
EP2981258A1 (en) 2016-02-10
BR112015025204A2 (pt) 2021-03-16
JP6415535B2 (ja) 2018-10-31
EP2981258B8 (en) 2020-11-11
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
MX2015014064A (es) 2017-04-13
US20160051507A1 (en) 2016-02-25
CN105431145A (zh) 2016-03-23
US20230201156A1 (en) 2023-06-29
DK2981258T3 (da) 2020-10-19
EP4696308A1 (en) 2026-02-18
HK1221152A1 (zh) 2017-05-26
JP6677779B2 (ja) 2020-04-08
AU2014248164B2 (en) 2019-05-23
MX367165B (es) 2019-08-07
KR20160014592A (ko) 2016-02-11
PT2981258T (pt) 2020-10-19
US9884039B2 (en) 2018-02-06
US20250339397A1 (en) 2025-11-06
WO2014165660A1 (en) 2014-10-09
JP2019001821A (ja) 2019-01-10
EP2981258A4 (en) 2016-10-05
EP3799869A1 (en) 2021-04-07
EP2981258B1 (en) 2020-08-12
EP3799869B1 (en) 2025-08-27
KR20210075211A (ko) 2021-06-22
SG10201709388QA (en) 2017-12-28
US20180303790A1 (en) 2018-10-25
IL241917B (en) 2020-10-29
CA2908935A1 (en) 2014-10-09
ES2823589T3 (es) 2021-05-07
KR102266460B1 (ko) 2021-06-17
US20200038364A1 (en) 2020-02-06
JP2016515623A (ja) 2016-05-30
AU2014248164A1 (en) 2015-10-15
US10272064B2 (en) 2019-04-30
CA2908935C (en) 2021-06-15
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
KR102493735B1 (ko) 퓨로세마이드의 피하 투여용 약학 제형
JP7001584B2 (ja) 安定化されたグルカゴン溶液
TWI674899B (zh) 醫藥配方
AU2025283539A1 (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2018516989A (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
EP3893843B1 (en) Pharmaceutical compositions of furosemide and uses thereof
HK40049405B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK40049405A (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK1221152B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
BR112015025204B1 (pt) Formulação farmacêutica líquida de furosemida e seu uso
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
DE102007014947A1 (de) Stabilisierte wässrige Lösungen von Ergolinverbindungen

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4